A5039223320- Systemic Lupus Erythematosus Research
- Platelet Disorders and Treatments
- Systemic Sclerosis and Related Diseases
- Renal Diseases and Glomerulopathies
- Monoclonal and Polyclonal Antibodies Research
- Diabetes and associated disorders
- Blood disorders and treatments
- Atherosclerosis and Cardiovascular Diseases
- T-cell and B-cell Immunology
- Salivary Gland Disorders and Functions
- Peripheral Neuropathies and Disorders
- Liver Diseases and Immunity
- Vasculitis and related conditions
- Hepatitis C virus research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Ocular Diseases and Behçet’s Syndrome
- Blood Coagulation and Thrombosis Mechanisms
- Rheumatoid Arthritis Research and Therapies
- Chronic Lymphocytic Leukemia Research
- Inflammatory Myopathies and Dermatomyositis
- Immunodeficiency and Autoimmune Disorders
- Parvovirus B19 Infection Studies
- Autoimmune and Inflammatory Disorders Research
- Lymphoma Diagnosis and Treatment
- Complement system in diseases
Hospital Clínic de Barcelona
2016-2025
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2016-2025
Universitat de Barcelona
2016-2025
Center for Rheumatology
2024
Karolinska University Hospital
2024
Karolinska Institutet
2024
University of Minnesota Medical Center
2024
Hospital Infantil Universitario Niño Jesús
2024
University of Pisa
2024
Autoimmune Technologies (United States)
2013-2021
Abstract Objective To analyze the clinical and immunologic manifestations of antiphospholipid syndrome (APS) in a large cohort patients to define patterns disease expression. Methods The serologic features APS (Sapporo preliminary criteria) 1,000 from 13 European countries were analyzed using computerized database. Results consisted 820 female (82.0%) 180 male (18.0%) with mean ± SD age 42 14 years at study entry. “Primary” was present 53.1% patients; associated systemic lupus erythematosus...
To develop new classification criteria for systemic lupus erythematosus (SLE) jointly supported by the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR).This international initiative had four phases. 1) Evaluation antinuclear antibody (ANA) as an entry criterion through systematic review meta-regression literature generation Delphi exercise, early patient cohort, a survey. 2) Criteria reduction nominal group technique exercises. 3) definition weighting...
Our objective was to update the EULAR recommendations for management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity prevention flares. Hydroxychloroquine is recommended all patients with lupus, dose not exceeding 5 mg/kg real body weight. During chronic...
To assess the efficacy/safety of B lymphocyte stimulator inhibitor belimumab plus standard therapy compared with placebo in active systemic lupus erythematosus (SLE).In a phase III, multicenter, randomized, placebo-controlled trial, 819 antinuclear antibody-positive or anti-double-stranded DNA-positive SLE patients scores ≥6 on Safety Estrogens Lupus Erythematosus National Assessment (SELENA) version Disease Activity Index (SLEDAI) were randomized 1:1:1 ratio to receive 1 mg/kg belimumab, 10...
In the present study, we assessed frequency and characteristics of main causes morbidity mortality in systemic lupus erythematosus (SLE) during a 10-year period compared early manifestations with those that appeared later evolution disease. 1990, started multicenter study 1,000 patients from 7 European countries. All had medical histories documented underwent interview routine general physical examination when entered all were followed prospectively by same physicians ensuing 10 years...
Abstract Objective Glomerulonephritis is a severe manifestation of systemic lupus erythematosus (SLE) that usually treated with an extended course intravenous (IV) cyclophosphamide (CYC). Given the side effects this regimen, we evaluated efficacy and toxicity low‐dose IV CYC prescribed as remission‐inducing treatment, followed by azathioprine (AZA) remission‐maintaining treatment. Methods In multicenter, prospective clinical trial (the Euro‐Lupus Nephritis Trial [ELNT]), randomly assigned 90...
In the present study we have analyzed prevalence and characteristics of most relevant clinical immunologic features in 1,000 patients with SLE. Several differences expression disease been observed relation to patients' age at onset, sex, autoantibody serology. The childhood-onset more often had malar rashes (55% vs 39%) nephropathy (28% 15%) as presenting manifestations. During evolution disease, these an increased only rash (79% 56%) a lower rheumatoid factor (6% 19%). older-onset (age 50...
The objective was to develop evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature review and expert opinion, overarching principles were formulated voted. High-risk antibody (aPL) profile is associated with greater risk thrombotic obstetric APS. Risk modification includes screening cardiovascular venous thrombosis factors, patient education about treatment adherence, lifestyle counselling. Low-dose...
Objectives To develop recommendations for the management of adult and paediatric lupus nephritis (LN). Methods The available evidence was systematically reviewed using PubMed database. A modified Delphi method used to compile questions, elicit expert opinions reach consensus. Results Immunosuppressive treatment should be guided by renal biopsy, aiming complete response (proteinuria <0.5 g/24 h with normal or near-normal function). Hydroxychloroquine is recommended all patients LN. Because...
To assess the prevalence of main causes morbi-mortality in antiphospholipid syndrome (APS) during a 10-year-follow-up period and to compare frequency early manifestations with those that appeared later.In 1999, we started an observational study 1000 APS patients from 13 European countries. All had medical histories documented when entered into were followed prospectively ensuing 10 years.53.1% primary APS, 36.2% associated systemic lupus erythematosus 10.7% other diseases. Thrombotic events...
<h3>Objective:</h3> Systemic lupus erythematosus (SLE) is a complex disease with variable presentations, course and prognosis. We sought to develop evidence-based recommendations addressing the major issues in management of SLE. <h3>Methods:</h3> The EULAR Task Force on SLE comprised 19 specialists clinical epidemiologist. Key questions for were compiled using Delphi technique. A systematic search PubMed Cochrane Library Reports was performed McMaster/Hedges queries' strategies related...
Objectives To develop recommendations for the diagnosis, prevention and treatment of neuropsychiatric systemic lupus erythematosus (NPSLE) manifestations. Methods The authors compiled questions on prevalence risk factors, diagnosis monitoring, therapy prognosis NPSLE. A systematic literature search was performed evidence categorised based sample size study design. Results Systemic (SLE) patients are at increased several Common (cumulative incidence >5%) manifestations include...
Anti-nuclear antibodies (ANA) are fundamental for the diagnosis of autoimmune diseases, and have been determined by indirect immunofluorescence assay (IIFA) decades. As demand ANA testing increased, alternative techniques were developed challenging classic IIFA. These platforms differ in their antigen profiles, sensitivity specificity, raising uncertainties regarding standardisation interpretation incongruent results. Therefore, an international group experts has created recommendations...
Rheumatic diseases in women of childbearing years may necessitate drug treatment during a pregnancy, to control maternal disease activity and ensure successful pregnancy outcome. This survey is based on consensus workshop international experts discussing effects anti-inflammatory, immunosuppressive biological drugs lactation. In addition, these male female fertility possible long-term infants exposed antenatally are discussed where data were available. Recommendations for lactation given.
Objective: To update the follow-up of Euro-Lupus Nephritis Trial (ELNT), a randomised prospective trial comparing low-dose (LD) and high-dose (HD) intravenous (IV) cyclophosphamide (CY) followed by azathioprine (AZA) as treatment for proliferative lupus nephritis. Patients methods: Data survival kidney function were prospectively collected during 10-year period 90 patients in ELNT, except 6 lost to follow-up. Results: Death, sustained doubling serum creatinine end-stage renal disease rates...
Background Long-term immunosuppressive treatment does not efficiently prevent relapses of lupus nephritis (LN). This investigator-initiated randomised trial tested whether mycophenolate mofetil (MMF) was superior to azathioprine (AZA) as maintenance treatment. Methods A total 105 patients with proliferative LN were included. All received three daily intravenous pulses 750 mg methylprednisolone, followed by oral glucocorticoids and six fortnightly cyclophosphamide 500 mg. Based on...